Cargando…

RAAS, ACE2 and COVID-19; a mechanistic review

The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in coronavirus disease 2019 (COVID-19) patients has been claimed as associated with the risk of COVID-19 infection and its subsequent morbidities and mortalities. These claims were resulting from the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elshafei, Ahmed, Khidr, Emad Gamil, El-Husseiny, Ahmed A., Gomaa, Maher H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270731/ https://www.ncbi.nlm.nih.gov/pubmed/34305426 http://dx.doi.org/10.1016/j.sjbs.2021.07.003

Ejemplares similares

Copeptin: a neuroendocrine biomarker of COVID-19 severity
por: Hammad, Reham, et al.
Publicado: (2022)

The clinical value of ficolin-3 gene polymorphism in rheumatic heart disease. An Egyptian adolescents study
por: Gomaa, Maher H., et al.
Publicado: (2021)

RAAS-Blockade in COVID-19: The Ace of Spades?
por: Agarwal, Krishna A., et al.
Publicado: (2021)

Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Reply to: ‘Interaction between RAAS inhibitors and ACE2 in the context of COVID-19’
por: Zheng, Ying-Ying, et al.
Publicado: (2020)

ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System
por: Michaud, Veronique, et al.
Publicado: (2020)

ACE2, SARS-CoV-2 und RAAS-Blocker
por: Kintscher, Ulrich, et al.
Publicado: (2021)

SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors
por: Milne, Stephen, et al.
Publicado: (2020)

1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies
por: Hagras, Mohamed, et al.
Publicado: (2021)

COVID-19 and RAAS inhibitors: is there a final conclusion?
por: Talebi-Taher, Mahshid, et al.
Publicado: (2021)

Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
por: Abulsoud, Ahmed I., et al.
Publicado: (2023)

Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors
por: Reddy, Paidi Ramakrishna, et al.
Publicado: (2021)

RAAS INHIBITORS ARE CARDIOPROTECTIVE IN PATIENTS WITH COVID-19
por: Holmes, Adam R., et al.
Publicado: (2021)

ACE2 Down-Regulation May Act as a Transient Molecular Disease Causing RAAS Dysregulation and Tissue Damage in the Microcirculatory Environment Among COVID-19 Patients
por: Ramos, Simone Gusmão, et al.
Publicado: (2021)

The RAAS Goodfellas in Cardiovascular System
por: Caputo, Ilaria, et al.
Publicado: (2023)

Inactive Matrix Gla Protein in Relation to Renal and Cardiac Functions and Cardiac Valvular Calcification Among Type 2 Diabetes Patients
por: Reda, Sara, et al.
Publicado: (2023)

RAAS inhibition and mortality in hypertension
por: Ferrari, Roberto
Publicado: (2013)

The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future
por: Zhang, Jishou, et al.
Publicado: (2020)

Aging- and gender-related modulation of RAAS: potential implications in COVID-19 disease
por: Monteonofrio, Laura, et al.
Publicado: (2020)

RAAS inhibitors do not increase the risk of COVID-19
por: Fernández-Ruiz, Irene
Publicado: (2020)

RAAS inhibitors in COVID-19: not all are created equal!
por: Kow, Chia Siang, et al.
Publicado: (2023)

COVID-19 and the RAAS—a potential role for angiotensin II?
por: Busse, Laurence W., et al.
Publicado: (2020)

Meta-analysis: RAAS inhibitors and COVID-19 positivity and/or mortality
Publicado: (2020)

Reply to: RAAS inhibitors in COVID-19: not all are created equal!
por: Gonçalves, Jorge, et al.
Publicado: (2023)

Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling
por: Wehbe, Zena, et al.
Publicado: (2020)

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) I: Endogenous Angiotensin Converting Enzyme (ACE) Inhibition
por: Fagyas, Miklós, et al.
Publicado: (2014)

Human pluripotent stem cell-derived functional sympathetic neurons express ACE2 and RAAS components: a framework for studying the effect of COVID-19 on sympathetic responsiveness
por: Wu, Hsueh-Fu, et al.
Publicado: (2022)

Risk of SARS-CoV-2 infection and COVID-19 prognosis with the use of renin–angiotensin–aldosterone system (RAAS) inhibitors: a systematic review
por: Iheanacho, Chinonyerem O., et al.
Publicado: (2021)

The other possible mechanism of the benefits of RAAS inhibition in the athogenesis of COVID‐19
por: Gupta, Neelesh, et al.
Publicado: (2020)

Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition
por: Ames, Marisa K, et al.
Publicado: (2016)

Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy
por: Ghazi, Lama, et al.
Publicado: (2017)

Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
por: Bernardi, Stella, et al.
Publicado: (2016)

Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19
por: Abd El-Aziz, Tarek Mohamed, et al.
Publicado: (2020)

The RAAS Axis and SARS-CoV-2: From Oral to Systemic Manifestations
por: Maranduca, Minela Aida, et al.
Publicado: (2022)

RAAS: A Convergent Player in Ischemic Heart Failure and Cancer
por: Garcia-Garduño, Texali C., et al.
Publicado: (2021)

Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
por: Wang, James Jiqi, et al.
Publicado: (2020)

A Shot in the Dark! RAAS Inhibitors Cause Severe COVID-19 Infection
por: Krishna, Bhuvana
Publicado: (2021)

RAAS inhibition and beyond—cardiovascular medications in patients at risk of or affected by COVID-19
por: Dutsch, Alexander, et al.
Publicado: (2023)

Antifibrotic Roles of RAAS Blockers: Update
por: Zhang, Ying-Ying, et al.
Publicado: (2019)

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) II: Albumin Suppresses Angiotensin Converting Enzyme (ACE) Activity in Human
por: Fagyas, Miklós, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_738glgricnlqaahcvbfs3iou60